BofA raised the firm’s price target on Gilead (GILD) to $154 from $144 and keeps a Buy rating on the shares. The firm, which switched its valuation method, says the company’s “steady” HIV franchise growth remains core to its Buy thesis as it sees upside from recent and upcoming launches.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead voluntarily recalls one lot of Veklury for Injection 100 mg/vial
- BKNG, GILD, ADI: 3 Stocks Flashing Strong Buy Signals on Technical Charts
- Gilead price target raised to $140 from $135 at Citi
- Gilead assumed with Buy from Neutral at UBS
- Gilead Sciences: PrEP-Led Growth, Easing HIV Overhangs, and Pipeline Upside Support Buy Rating and 2027 Re-Rating Target